Trichomoniasis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Trichomoniasis Epidemiology Forecast Report Coverage

Expert Market Research's “Trichomoniasis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of trichomoniasis. It projects the future incidence and prevalence rates of trichomoniasis cases across various populations. The study covers age, gender, and type as major determinants of the trichomoniasis population. The report highlights patterns in the prevalence of trichomoniasis over time and projects future trends based on multiple variables.

Trichomoniasis Understanding: Disease Overview

Trichomoniasis is a common sexually transmitted infection caused by the protozoan Trichomonas vaginalis. It affects both women and men, often asymptomatically, but can cause vaginal discharge, itching, dysuria, and pelvic discomfort in women. Men may experience urethral irritation or remain asymptomatic carriers. Infection increases susceptibility to other STIs, including HIV, and may contribute to adverse pregnancy outcomes. Diagnosis is typically confirmed through nucleic acid amplification tests (NAATs) or wet mount microscopy. Timely identification and treatment are essential to prevent complications and interrupt transmission.

Trichomoniasis Epidemiology Perspective

The trichomoniasis epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for trichomoniasis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for trichomoniasis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Trichomoniasis, caused by Trichomonas vaginalis, is the world’s most common non‑viral sexually transmitted infection, with approximately 156 million new cases globally in 2020 (73.7 million in women, 82.6 million in men).
• Men generally show higher incidence rates, while women experience a greater symptomatic and reproductive health burden.
• Most infections occur in adults aged 15-49, with many cases in women leading to complications and higher disability-adjusted life years (DALYs).
• Prevalence varies by region, with about one third of new infections occurring in the WHO African Region, followed by the region of the Americas, highlighting notable geographic differences in disease burden.

Read more about this report - Request a Free Sample

Country-wise Trichomoniasis Epidemiology

The trichomoniasis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Trichomoniasis is recognized as the most prevalent non‑viral sexually transmitted infection in the United States, affecting an estimated 2.6 million people; national surveillance shows a 2.1% prevalence among females and 0.5% among males, with notably higher rates among Black females (9.6%) and males (3.6%) compared with other groups. Because trichomoniasis is not nationally reportable and routine screening isn’t recommended, many of these patterns are derived from population and clinic studies. Many individuals show minimal or no symptoms, underscoring the importance of awareness and prevention efforts to address health disparities and reduce transmission. Across Europe and Asia, including Germany, Spain, Italy, France, the United Kingdom, Japan, and India, trichomoniasis prevalence is generally considered lower than in the United States; however, limited routine screening and the absence of mandatory national reporting in many countries likely contribute to underestimation of the true disease burden.

Trichomoniasis: Treatment Overview

Trichomoniasis is primarily treated with antiprotozoal therapy, most commonly metronidazole or tinidazole, administered orally in single or multi-day regimens. Sexual partners should be simultaneously treated to prevent reinfection. Resistance to first-line therapy is rare but may require alternative or extended treatment. Symptomatic relief includes maintaining genital hygiene and avoiding sexual activity until therapy completion. Education on safe sexual practices, regular STI screening, and prompt treatment of partners are critical for long-term control. Follow-up testing ensures resolution and reduces the risk of reinfection.

Key Questions Answered

• What are the key findings of trichomoniasis epidemiology in the 8 major markets?
• What will be the total number of patients with trichomoniasis across the 8 major markets during the forecast period?
• What was the country-wise trichomoniasis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of trichomoniasis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of trichomoniasis during the forecast period of 2026-2035?
• What are the currently available treatments for trichomoniasis?
• What are the disease risks, signs, symptoms, and unmet needs of trichomoniasis?

Scope of the Trichomoniasis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of trichomoniasis based on several factors.
• Trichomoniasis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The trichomoniasis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Trichomoniasis Market

Human Immunodeficiency Virus (HIV1) Infection Market